SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

8 marketing jobs

Xeris Pharmaceuticals, Inc. logo
8 days ago

Associate Director, Omnichannel Marketing Execution

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$155K/yr – $233K/yr
Xeris Pharmaceuticals, Inc. logo
2 months ago

Associate Manager, Marketing - Neurology (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$99K/yr – $120K/yr
Xeris Pharmaceuticals, Inc. logo
2 months ago

Senior Director, Pipeline Marketing Lead

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$223K/yr – $268K/yr
Xeris Pharmaceuticals, Inc. logo
2 months ago

Associate Manager, Marketing – Endocrinology (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$80K/yr – $140K/yr
Xeris Pharmaceuticals, Inc. logo
2 months ago

Associate Director, Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$170K/yr – $190K/yr
Xeris Pharmaceuticals, Inc. logo
2 months ago

Associate Director, HCP Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$140K/yr – $230K/yr
Xeris Pharmaceuticals, Inc. logo
3 months ago

Associate Manager, Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$99K/yr – $120K/yr
Xeris Pharmaceuticals, Inc. logo
4 months ago

Associate Director, Marketing Rare Disease

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$170K/yr – $195K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

8 jobs
Xeris Pharmaceuticals, Inc. logo

Associate Director, Omnichannel Marketing Execution

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$155K/yr - $233K/yrIn-houseFull-timeSenior level7+ years exp.
8 days ago
Xeris Pharmaceuticals, Inc. logo

Associate Manager, Marketing - Neurology (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$99K/yr - $120K/yrIn-houseFull-timeMid level3+ years exp.
2 months ago
Xeris Pharmaceuticals, Inc. logo

Senior Director, Pipeline Marketing Lead

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$223K/yr - $268K/yrIn-houseFull-timeSenior level12+ years exp.
2 months ago
Xeris Pharmaceuticals, Inc. logo

Associate Manager, Marketing – Endocrinology (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$80K/yr - $140K/yrIn-houseFull-timeMid level3+ years exp.
2 months ago
Xeris Pharmaceuticals, Inc. logo

Associate Director, Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$170K/yr - $190K/yrIn-houseFull-timeDirector/executive8+ years exp.
2 months ago
Xeris Pharmaceuticals, Inc. logo

Associate Director, HCP Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$140K/yr - $230K/yrIn-houseFull-timeSenior level8+ years exp.
2 months ago
Xeris Pharmaceuticals, Inc. logo

Associate Manager, Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$99K/yr - $120K/yrIn-houseFull-timeMid level3+ years exp.
3 months ago
Xeris Pharmaceuticals, Inc. logo

Associate Director, Marketing Rare Disease

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$170K/yr - $195K/yrIn-houseFull-timeSenior level8+ years exp.
4 months ago
Xeris Pharmaceuticals, Inc. logo
Xeris Pharmaceuticals, Inc.

Associate Director, Omnichannel Marketing Execution

Chicago, IL (Hybrid)

$155K/yr – $233K/yrSenior Level7+ years expFull time

Posted 8 days ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the end-to-end omnichannel journey strategy for three brands, translating brand imperatives into dynamic, trigger-based journeys for HCP and patient/DTC audiences, while coordinating with Commercial Operations, Analytics, and Paid Media. Lead audience segmentation, field and feedback signals, test-and-learn plans, and cross-functional collaboration to improve journey performance and connect to TRx outcomes.

  • Drive dynamic, trigger-based journeys across HCP and patient/DTC audiences.
  • Define channel sequencing, analytics, and measurement in partnership with brand and operations teams.
  • Manage cross-functional stakeholders and agency relationships to execute the omnichannel blueprint.

Job Description

Responsibilities

  • Translate each brand’s strategic imperatives into an omnichannel customer journey blueprint, covering both HCP and patient/DTC segments and reflecting each segment’s distinct decision path.
  • Serve as the strategic connector between brand marketing teams, Commercial Operations and Analytics, and the in-house Paid Media/digital team, translating brand priorities into journey requirements and measurement plans.
  • Define audience segmentation and channel-reachability strategy for each brand’s HCP and patient populations, determining which channels reach which segments most effectively before journey design begins.
  • Design dynamic, trigger-based journeys, not static, one-time sequences, that move HCP and patient audiences across channels based on real-time behavioral and engagement signals, incorporating next-best-action logic so the channel and content an HCP or patient sees reflects their most recent engagement rather than a fixed sequence.
  • Define the field-facing trigger logic: what signals warrant a rep alert, what threshold of engagement constitutes a meaningful signal, and how that alert integrates into the sales workflow.
  • Define what signals feed back into the journey engine to advance an HCP or patient to the next best action or channel.
  • Prioritize journey build and enhancement work across all three brands in partnership with the Sr. Director, sequencing brands by commercial priority and current build maturity rather than treating all three as day-one scope.
  • Collaborate with Paid Media team to define how each channel functions within the omnichannel journey, defining the sequencing, role, and cadence of paid social, EHR/point-of-care, PulsePoint and other programmatic, endemic, Google paid search, conferences and peer-to-peer events, and owned website activity.
  • Design and manage test-and-learn plans across channel mix, message, and cadence to continuously improve journey performance; partner with Analytics on measurement design, reporting, and connecting journey performance to TRx outcomes.
  • Direct-manage the Manager, Marketing Technology & Journey Operations, leading journey strategy and design together while the Manager owns backend implementation and technical build (Veeva CRM, marketing orchestration platform); ensure the build executes the strategic blueprint accurately.

Requirements

  • Bachelor’s degree in business, marketing, advertising, or other relevant field of study.
  • 7 to 10 years of marketing experience in pharmaceutical, biotech, or specialty healthcare, with direct experience in omnichannel or CRM/marketing technology strategy.
  • Demonstrated experience building or managing dynamic, trigger-based customer journeys (not static campaign sequences) in a regulated environment.
  • Working knowledge of Veeva CRM and a marketing orchestration/ESP platform (HubSpot, Marketo/Adobe, Salesforce or equivalent); familiarity with CDP concepts a plus.
  • Experience across both HCP and patient/DTC marketing; multi-brand experience strongly preferred.
  • People management experience, with the ability to direct technical execution without owning the build personally.
  • Strong cross-functional stakeholder management skills in a matrixed pharma organization, including commercial operations, market access, medical affairs, brand, and agencies.
  • Comfort operating in ambiguity. This role will build net-new journey infrastructure on some brands while enhancing a mature journey on another, often in parallel.
  • Strong understanding of FDA regulations and guidance governing HCP and patient promotional communications within the pharmaceutical industry.
  • Veeva CRM exposure required

Benefits

  • The Company also offers a comprehensive benefits package that includes additional elements such as paid time off benefits, various health, vision, and dental insurance options, 401(k) retirement benefits and more for eligible employees.
Xeris Pharmaceuticals, Inc. logo

Xeris Pharmaceuticals, Inc.

3.7 Glassdoor

We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

Founded in 2005
Chicago, Illinois, USA
445 employees (21 in marketing)
www.xerispharma.com
69% recommend to a friend
100% CEO approval

Salaries

Posted range

$155K/yr – $233K/yr

Taken straight from the job posting.

See all Xeris Pharmaceuticals, Inc. salaries

Marketing Team

Marketing Team Size
19 (4% of company)
Median Career Experience
10 years
Median Tenure
2.5 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Caela Ancona
Caela Ancona
Associate Manager, Marketing Operations
At the company for 10 months

Funding

Total Funding
$548.5M
Last Raise
$200M
Post IPO Debt, 2 years ago

Funding History

  • Mar 2024
    Post IPO Debt • $200M
  • Jan 2022
    Post IPO Equity • $30M
  • Mar 2021
    Post IPO Equity • $27M

Traffic Signals

Monthly Visitors
7.9K
Traffic Source Mix
Search
37.1%
Direct
45.5%
Referral
7.1%
Social
8.8%
Paid
1.5%

Headcount Trend

Current headcount: ~445

Recent News

A Look at Xeris Biopharma (XERS) Valuation After Patent Progress on Novel Hypothyroidism Therapy
Dec 2, 2025 • Sahm
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121
Dec 1, 2025 • TipRanks
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121
Dec 1, 2025 • Stock Titan
Xeris Biopharma Reports Strong Q3 2025 Financial Results
Nov 6, 2025 • TipRanks
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
Nov 6, 2025 • Business Wire
Xeris Pharmaceuticals stock hits 52-week high at $10.03 By Investing.com
Nov 6, 2025 • Investing.com Nigeria
What Xeris Biopharma Holdings (XERS)'s Strong Revenue Growth and Pipeline Advances Mean For Shareholders
Oct 29, 2025 • Sahm
Xeris Biopharma Holdings (XERS): Evaluating Valuation After a Strong Share Price Rally
Oct 27, 2025 • Sahm
Has the Recent 166% Rally Left Xeris Biopharma Fully Priced in 2025?
Oct 25, 2025 • Sahm
Xeris Pharmaceuticals stock reaches 52-week high at $9.41
Oct 24, 2025 • Investing.com
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Oct 23, 2025 • Business Wire
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 13% Over Last Week
Oct 16, 2025 • 富途牛牛
Xeris Pharmaceuticals stock hits 52-week high at 8.53 USD
Oct 15, 2025 • Investing.com
Xeris Biopharma's Path Toward Profitability Might Change The Case For Investing In XERS
Oct 5, 2025 • Sahm
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Oct 3, 2025 • Yahoo Finance
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 3, 2025 • Business Wire
Xeris Pharmaceuticals stock hits 52-week high at 8.36 USD
Oct 2, 2025 • Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $8.03
Sep 18, 2025 • Investing.com
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
Sep 13, 2025 • 富途牛牛
Xeris Pharmaceuticals stock hits 52-week high at 8.02 USD
Sep 3, 2025 • Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $7.96
Aug 26, 2025 • Investing.com
Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book
Aug 25, 2025 • Stock Titan
Xeris Biopharma receives new patent for Recorlev extending to 2040
Aug 25, 2025 • Investing.com
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
Aug 25, 2025 • Business Wire
Xeris Pharmaceuticals stock hits 52-week high at $7.72
Aug 18, 2025 • Investing.com
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Aug 12, 2025 • Yahoo Finance
Xeris Biopharma assumed with a Buy at H.C. Wainwright
Aug 12, 2025 • thefly.com
Xeris Pharmaceuticals stock hits 52-week high at 7.13 USD
Aug 11, 2025 • Investing.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 10, 2025 • Sahm
Earnings call transcript: Xeris Pharmaceuticals beats Q2 2025 forecasts, stock surges
Aug 7, 2025 • Investing.com
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
Aug 7, 2025 • Business Wire
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
Aug 7, 2025 • BioSpace
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
Jul 31, 2025 • Business Wire
A Piece Of The Puzzle Missing From Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) 25% Share Price Climb
Jul 15, 2025 • simplywall.st
Xeris Biopharma projects $1 billion Recorlev revenue by 2035
Jun 3, 2025 • Investing.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
Jun 3, 2025 • Business Wire
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
Jun 3, 2025 • MarketScreener
Xeris Biopharma Holdings Reaffirms 2025 Revenue Guidance Of $260-$275 Million
Jun 3, 2025 • MarketScreener
Earnings call transcript: Xeris Pharmaceuticals Q1 2025 revenue up 48%, stock rises
May 8, 2025 • Investing.com
Xeris Biopharma raises revenue guidance for 2025 to $260M-$275M amid strong Recorlev growth
May 8, 2025 • Seeking Alpha
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 8, 2025 • MarketScreener
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 8, 2025 • Morningstar.com
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
May 1, 2025 • BioSpace
Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long
Apr 29, 2025 • simplywall.st
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
Apr 26, 2025 • Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc.
Apr 15, 2025 • Defense World
Raymond James Financial Inc. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Apr 14, 2025 • Defense World
Global Subcutaneous Biologics Market to Surpass USD 236 Billion with Advancements in Self-Administration Devices and Drug Delivery Technologies
Apr 1, 2025 • Research and Markets
Xeris Pharmaceuticals (XERS) Announces Board Changes
Mar 28, 2025 • StreetInsider.com
Xeris Announces Changes to Its Board of Directors
Mar 28, 2025 • Business Wire
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Mar 17, 2025 • Business Wire
Xeris Pharmaceuticals Inc. (XERS) Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx
Mar 17, 2025 • StreetInsider.com
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Mar 17, 2025 • BioSpace
Xeris Biopharma - Possibly The Best Pharma Stock
Mar 11, 2025 • Barchart
Xeris Pharmaceuticals stock hits 52-week high at $4.13
Mar 6, 2025 • Investing.com
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
Mar 6, 2025 • Business Wire
Earnings call transcript: Xeris Pharmaceuticals Q4 2024 beats EPS forecast, stock surges
Mar 6, 2025 • Investing.com
Xeris Pharmaceuticals Inc. (XERS) Files $250M Mixed Shelf
Mar 6, 2025 • StreetInsider.com
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
Feb 24, 2025 • Business Wire
Xeris to Participate in Upcoming Investor Conferences
Feb 5, 2025 • BioSpace
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
Jan 21, 2025 • PR Newswire
Piper Sandler Downgrades Xeris Biopharma Hold...
Nov 11, 2024 • Benzinga
Xeris Biopharma price target raised by 60c at H.C. Wainwright, here's why
Nov 11, 2024 • thefly.com
Xeris Biopharma price target raised by 60c at H.C. Wainwright, here's why
Nov 11, 2024 • thefly.com
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25, 2024 • Seeking Alpha
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying
Aug 13, 2024 • TradingView
Xeris Biopharma announces CEO succession
Jul 11, 2024 • Crain's Chicago Business
Xeris Biopharma Announces CEO Succession Plan
Jul 10, 2024 • Business Wire
Xeris Biopharma Announces CEO Succession Plan
Jul 8, 2024 • Xeris Biopharma Holdings, Inc.
Xeris Biopharma Announces CEO Succession Plan
Jul 8, 2024 • BioSpace
Xeris stock jumps 14% on Phase 2 data for injected levothyroxine (NASDAQ:XERS)
May 30, 2024 • Seeking Alpha
Xeris to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 • Business Wire
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once ...
May 29, 2024 • Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
May 29, 2024 • Business Wire
Xeris Pharmaceuticals stock price target cut on Q1 results By Investing.com
May 29, 2024 • Investing.com
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
May 2, 2024 • Business Wire
Post-Bariatric Hypoglycemia Market Poised for Growth by 2032, Projects DelveInsight | XOMA, Zealand Pharma A/S ...
Apr 26, 2024 • Barchart.com
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 3, 2024 • Business Wire
Xeris Pharmaceuticals shares target upgraded on expected revenue growth
Mar 29, 2024 • Investing.com
Xeris Pharmaceuticals, Inc. on LinkedIn: This is a presentation you won't want to miss! Xeris Chairman and CEO…
Jan 8, 2024 • LinkedIn
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 5, 2024 • Business Wire
Severe Hypoglycemia Treatment Market is Likely to Upsurge ...
Dec 9, 2023 • Artrocker
Xeris Biopharma Reports Third Quarter 2023 Financial Results
Nov 23, 2023 • Business Wire
Xeris Pharmaceuticals GAAP EPS of -$0.09 beats by $0.03, revenue of $48.32M beats by $7.24M
Nov 9, 2023 • SeekingAlpha
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
Oct 16, 2023
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
Sep 27, 2023
Why Xeris Pharmaceuticals Is Soaring 7% Higher Today
Jan 1, 1970 • Yahoo Finance
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
Jan 1, 1970 • BioSpace
Xeris Pharmaceuticals Enters Collaboration Agreement With Merck
Jan 1, 1970 • Biospace
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
Jan 1, 1970 • Xeris Biopharma Holdings, Inc.
Xeris Pharmaceuticals reports Q2 revenue
Jan 1, 1970 • SeekingAlpha
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
Jan 1, 1970 • BioSpace
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
Jan 1, 1970 • BioSpace
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 1, 1970 • PharmiWeb.com
Belay Diagnostics signs lease at Trammell Crow's Fulton Labs
Jan 1, 1970 • Urbanize Chicago

Links

www.xerispharma.comLinkedInX (Twitter)Crunchbase